Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRPF1 | P55201 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5943420 | 0.77 | BRPF1 (0.38) | BRPF1GAASMN1; SMN2KMT2AMAOA | |
| SCHEMBL8333405 | 0.76 | GAA (0.31) | GAASMN1; SMN2 | |
| SCHEMBL3120276 | 0.74 | GAA (0.31) | GAASMN1; SMN2 | |
| SCHEMBL7345762 | 0.74 | GAA (0.34) | GAASMN1; SMN2 | |
| SCHEMBL1598178 | 0.74 | GAA (0.31) | GAASMN1; SMN2 | |
| SCHEMBL7603127 | 0.72 | — | — | |
| SCHEMBL22505286 | 0.70 | MAOA (0.42) | BRPF1GAAKMT2AMAOA | |
| SCHEMBL24458214 | 0.70 | NOX1 (0.32) | — | |
| SCHEMBL8338720 | 0.69 | GAA (0.32) | GAASMN1; SMN2 | |
| SCHEMBL8336770 | 0.69 | GAA (0.32) | BRPF1GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022109329-A1 | TRICYCLIC COMPOUNDS AND RELATED COMPOSITIONS, ZINC ELECTROCHEMICAL CELLS, BATTERIES, METHODS AND SYSTEMS | ALIONYX ENERGY SYSTEMS (US) | 2022-05-27 | — | — | WO | disclosed |
| EP-2170975-B1 | COMPOSITIONS AND METHODS FOR PRODUCING CELLULAR LABELS FOR NUCLEAR MAGNETIC RESONANCE TECHNIQUES | UNIV CARNEGIE MELLON (US) | 2018-05-02 | — | — | EP | disclosed |
| US-8227610-B2 | Compositions and methods for producing cellular labels for nuclear magnetic resonance techniques | CARNEGIE MELLON UNIVERSITY (US) | 2012-07-24 | — | — | US | disclosed |
| US-20090074673-A1 | Compositions and methods for producing cellular labels for nuclear magnetic resonance techniques | CARNEGIE MELLON UNIVERSITY (US) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090074673-A1 | Compositions and methods for producing cellular labels for nuclear magnetic resonance techniques | NES, MKI67, CD68 | BRPF1 3213/4885GAA 1291/4885SMN1; SMN2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.